当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:204.84亿  总市值:243.51亿
流通股本:6.30亿   总股本:7.49亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,273,147,554.37835,220,095.37393,009,966.081,741,329,969.61
  收到的税费返还6,368,337.793,521,200.65806,423.224,566,588.32
  收到其他与经营活动有关的现金43,956,095.0337,237,275.8435,988,568.2265,490,488.22
  经营活动现金流入小计1,323,471,987.19875,978,571.86429,804,957.521,811,387,046.15
  购买商品、接受劳务支付的现金401,692,918.2255,061,869.13109,851,243.37564,165,327.08
  支付给职工以及为职工支付的现金528,437,549.04362,670,351.19202,650,410.26676,070,205.23
  支付的各项税费52,826,422.9944,636,272.5826,290,323.55118,651,811.76
  支付其他与经营活动有关的现金74,123,947.6450,837,084.1325,863,779.18113,570,983.68
  经营活动现金流出小计1,057,080,837.87713,205,577.03364,655,756.361,472,458,327.75
  经营活动产生的现金流量净额266,391,149.32162,772,994.8365,149,201.16338,928,718.4
二、投资活动产生的现金流量:
  收回投资收到的现金1,903,795,691.671,017,911,291.67611,998,0003,160,885,508.22
  取得投资收益收到的现金62,042,621.8520,527,967.295,612,767.24194,848,031.42
  处置固定资产、无形资产和其他长期资产收回的现金净额1,145,178.4636,965.242,945.24568,427.13
  收到的其他与投资活动有关的现金---9,200,000
  投资活动现金流入小计1,966,983,491.981,038,476,224.2617,613,712.483,365,501,966.77
  购建固定资产、无形资产和其他长期资产支付的现金121,121,329.5689,303,769.2446,814,440.04269,391,239.71
  投资支付的现金2,110,584,774.911,384,184,774.91904,759,050.915,059,134,712.6
  投资活动现金流出小计2,231,706,104.471,473,488,544.15951,573,490.955,328,525,952.31
  投资活动产生的现金流量净额-264,722,612.49-435,012,319.95-333,959,778.47-1,963,023,985.54
三、筹资活动产生的现金流量:
  分配股利、利润或偿付利息支付的现金22,385,229--119,633,363.2
  支付其他与筹资活动有关的现金36,603,316.9128,180,254.5718,665,128.1145,994,123.77
  筹资活动现金流出小计58,988,545.9128,180,254.5718,665,128.1265,627,486.97
  筹资活动产生的现金流量净额-58,988,545.91-28,180,254.57-18,665,128.1-265,627,486.97
四、汇率变动对现金及现金等价物的影响-5,822,610.67-2,551,375.3-1,154,223.861,278,854.73
五、现金及现金等价物净增加额-63,142,619.75-302,970,954.99-288,629,929.27-1,888,443,899.38
  加:期初现金及现金等价物余额965,203,128.59965,203,128.59965,201,085.722,853,647,027.97
  期末现金及现金等价物余额902,060,508.84662,232,173.6676,571,156.45965,203,128.59
补充资料:
  净利润-60,932,376.38-69,755,063.9
  资产减值准备-66,010,456.08-66,540,016.67
  固定资产和投资性房地产折旧-45,228,713.36-86,371,570.67
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-45,228,713.36-86,371,570.67
  无形资产摊销-8,041,663.14-15,255,792.01
  长期待摊费用摊销-10,656,937.26-17,890,874.87
  递延收益摊销-8,924,489.34--6,566,775.31
  处置固定资产、无形资产和其他长期资产的损失-44,025.87-48,130.43
  固定资产报废损失--152,132.42-161,723.95
  公允价值变动损失--107,019,073.28-127,048,597.78
  财务费用--30,344,182.68--56,311,351.88
  投资损失--13,135,262.03--36,011,545.69
  递延所得税-1,267,989.53--40,245,864.96
  其中:递延所得税资产减少-3,917,588.08--5,105,168.52
    递延所得税负债增加--2,649,598.55--35,140,696.44
  存货的减少--24,389,766.63-384,195,565.07
  经营性应收项目的减少-84,804,281.28--5,146,312.12
  经营性应付项目的增加-43,202,349.46--331,889,262.21
  现金的期末余额-662,232,173.6-965,203,128.59
  减:现金的期初余额-965,203,128.59-2,853,647,027.97
  现金及现金等价物的净增加额--302,970,954.99--1,888,443,899.38
公告日期2025-10-312025-08-272025-04-292025-03-29
审计意见(境内)标准无保留意见
TOP↑